Department of General Surgery, Digestive Medical Center, The First Affiliated Hospital, School of Medicine, Tsinghua University, Beijing 100016, China.
World J Gastroenterol. 2011 Apr 7;17(13):1685-9. doi: 10.3748/wjg.v17.i13.1685.
Hepatocellular carcinoma (HCC) is one of the most common malignancies, ranking the sixth in the world, with 55% of cases occurring in China. Usually, patients with HCC did not present until the late stage of the disease, thus limiting their therapeutic options. Although surgical resection is a potentially curative modality for HCC, most patients with intermediate-advanced HCC are not suitable candidates. The current therapeutic modalities for intermediate-advanced HCC include: (1) surgical procedures, such as radical resection, palliative resection, intraoperative radiofrequency ablation or cryosurgical ablation, intraoperative hepatic artery and portal vein chemotherapeutic pump placement, two-stage hepatectomy and liver transplantation; (2) interventional treatment, such as transcatheter arterial chemoembolization, portal vein embolization and image-guided locoregional therapies; and (3) molecularly targeted therapies. So far, how to choose the therapeutic modalities remains controversial. Surgeons are faced with the challenge of providing the most appropriate treatment for patients with intermediate-advanced HCC. This review focuses on the optional therapeutic modalities for intermediate-advanced HCC.
肝细胞癌 (HCC) 是最常见的恶性肿瘤之一，在全球排名第六，其中 55%的病例发生在中国。通常，HCC 患者直到疾病晚期才出现，从而限制了他们的治疗选择。尽管手术切除是 HCC 的一种潜在治愈方法，但大多数中晚期 HCC 患者不适合手术。中晚期 HCC 的当前治疗方法包括：(1)手术治疗，如根治性切除术、姑息性切除术、术中射频消融或冷冻手术消融、术中肝动脉和门静脉化疗泵放置、两阶段肝切除术和肝移植；(2)介入治疗，如经导管动脉化疗栓塞术、门静脉栓塞术和图像引导局部治疗；和 (3)分子靶向治疗。到目前为止，如何选择治疗方法仍存在争议。外科医生面临着为中晚期 HCC 患者提供最合适治疗的挑战。本综述重点介绍了中晚期 HCC 的可选治疗方法。
